ArticleNPJ precision oncology2025

Targeting SIX2 as a novel sensitization strategy of sorafenib treatment on advanced hepatocellular carcinoma through modulating METTL9-SLC7A11 axis.

Junren Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.